Insider Selling: Outset Medical, Inc. (NASDAQ:OM) CEO Sells 935 Shares of Stock

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 935 shares of the stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $17.80, for a total value of $16,643.00. Following the sale, the chief executive officer now directly owns 58,129 shares in the company, valued at $1,034,696.20. This represents a 1.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Leslie Trigg also recently made the following trade(s):

• On Tuesday, February 18th, Leslie Trigg sold 974 shares of Outset Medical stock. The stock was sold at an average price of $13.50, for a total value of $13,149.00.

Outset Medical Trading Down 0.3%

Shares of Outset Medical stock opened at $19.50 on Friday. The firm has a market capitalization of $70.10 million, a PE ratio of -7.86 and a beta of 1.90. Outset Medical, Inc. has a twelve month low of $5.85 and a twelve month high of $72.60. The firm’s 50-day moving average price is $11.57 and its 200 day moving average price is $12.81. The company has a current ratio of 6.49, a quick ratio of 5.04 and a debt-to-equity ratio of 4.12.

Outset Medical (NASDAQ:OM) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($3.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($2.69). The company had revenue of $29.75 million during the quarter, compared to analysts’ expectations of $27.81 million. Outset Medical had a negative net margin of 112.57% and a negative return on equity of 175.64%. On average, sell-side analysts predict that Outset Medical, Inc. will post -1.99 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of OM. Two Sigma Securities LLC lifted its stake in Outset Medical by 190.0% in the 4th quarter. Two Sigma Securities LLC now owns 42,477 shares of the company’s stock worth $47,000 after purchasing an additional 27,830 shares in the last quarter. XTX Topco Ltd purchased a new position in Outset Medical in the 4th quarter worth approximately $50,000. TD Asset Management Inc purchased a new position in Outset Medical in the 1st quarter worth approximately $589,000. Squarepoint Ops LLC purchased a new position in Outset Medical in the 4th quarter worth approximately $174,000. Finally, Parkman Healthcare Partners LLC purchased a new position in Outset Medical in the 1st quarter worth approximately $2,556,000.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Royal Bank of Canada increased their price target on Outset Medical from $12.00 to $14.00 and gave the stock a “sector perform” rating in a research report on Thursday, May 8th. Stifel Nicolaus set a $15.00 price target on Outset Medical in a research report on Friday, March 21st.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.